Research for a future without Alzheimer’s diseaseBarcelona - Spanien
Every day, thousands of new cases of Alzheimer’s disease are diagnosed in the world. This disease has devastating effects, and, at the moment, it has no cure. It affects 1 out of 10 people of over 65 years and one third of people over 85 years. To this date, 50 million people in the world suffer from dementia, over 800,000 people in Spain. With an increasing life expectancy, if no effective cure is found, in 2050 the number of cases will have multiplied by three, reaching epidemic proportions.
Finanzierte Gesamtsumme €100%finanziert
Viena Kunden 240.457€
Diejenigen Personen, die auf natürliche Art direkt von den im Projekt ausgeführten Aktionen begünstigt wurden.
Diejenigen identifizierbaren Personen, die einen potentiellen Effekt von den im Projekt durchgeführten Aktionen erfahren.
- Materialien 95.000€
- Personal 143.838€
- Gesamt 238.838€
Research on Alzheimer’s disease is experiencing a real paradigm shift. The focus is currently on the pre-clinical phase of the disease, characterized by a series of structural and functional changes that occur in the brain up to 20 years before the manifestation of the first clinical symptoms. This explains that many of the clinical trials conducted up to this date have failed, as measures have been taken on patients whose disease already has a long course.
Barcelonaβeta Brain Research Center (BBRC), a centre promoted by the Pasqual Maragall Foundation, specializes in the research of the pre-clinical phase of Alzheimer’s disease, in order to be able to prevent it. For this purpose, it carries out primary and secondary disease prevention projects, in addition to neuroimaging studies and studies regarding the cognitive functions affected by aging.
The first research clinic in the world was established to reveal the risk of developing dementia in 5 years in persons who complain of subjective memory loss, in order to offer them a personalized action plan that allows them to reduce their risk.
Study participants receive primary prevention advice to reduce the modifiable disease risk factors and have the possibility of participating in secondary prevention projects and in clinical trials of disease prevention.
Wer wird begünstigt?
Thanks to the contributions of this study, the risk of having Alzheimer’s disease could be determined in 15 years and, if the way to prevent the disease when it starts to develop in the brain is found, treatments for their prevention could be provided. Those who are currently 30 years old would be the first to benefit from this, over 3 million people in Spain
To prevent Alzheimer’s disease conducting trials with new treatments and creating protocols for Alzheimer’s disease.